EGFR and non-small cell lung carcinoma: Since the low incidence of the stage IIII–IV LSCC patients (only 20~30% in NSCLC) and the natural characteristics of EGFR mutation in this kind of population (only 2.7% in LSCC), the small number of patients in the validation dataset is another limitation.